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The antitumor agent 11β (CAS # 865070-
37-7), consisting of a DNA damaging aniline 
mustard linked to an androgen receptor (AR) 
ligand, is known to form covalent DNA adducts 
and to induce apoptosis potently in AR-positive 
prostate cancer cells in vitro; it also strongly 
prevents growth of LNCaP xenografts in mice.  
The present study describes the unexpectedly 
strong activity of 11β against the AR-negative 
HeLa cells, both in cell culture and tumor 
xenografts, and uncovers a new mechanism of 
action that likely explains this activity. Cellular 
fractionation experiments indicated that 
mitochondria are the major intracellular sink 
for 11β; flow cytometry studies showed that 11β 
exposure rapidly induced oxidative stress, 
mitochondria being an important source of 
reactive oxygen species (ROS). Additionally, 
11β inhibited oxygen consumption both in 
intact HeLa cells and in isolated mitochondria. 
Specifically, 11β blocked uncoupled oxygen 
consumption when mitochondria were 
incubated with complex I substrates, but it had 
no effect on oxygen consumption driven by 
substrates acting downstream of complex I in 
the mitochondrial electron transport chain. 
Moreover, 11β enhanced ROS generation in 
isolated mitochondria, suggesting that complex 
I inhibition is responsible for ROS production. 
At the cellular level, the presence of 
antioxidants (N-acetylcysteine or vitamin E) 
significantly reduced the toxicity of 11β, 
implicating ROS production as an important 
contributor to cytotoxicity. Collectively, our 
findings establish complex I inhibition and ROS 
generation as a new mechanism of action for 
11β, which supplements conventional DNA 
adduct formation to promote cancer cell death. 
 
 
Adaptive responses to hypoxia and oxidative 
stress allow tumor cells to exist and grow under 
adverse conditions and to acquire therapeutic 
resistance, contributing to the failure of 
chemotherapy for prostate and other cancers (1).  
Strategies to overcome resistance include 
development of agents with multiple cytotoxic 
mechanisms; such strategies could include a 
primary toxicity mechanism (e.g., DNA damage) 
that is complemented by a secondary stressor, such 
as the intentional generation of oxidative stress or 
the inhibition of natural antioxidant enzymes (2).  
In fact, many clinically useful drugs have more 
than one mechanism of toxicity. Reactive oxygen 
species (ROS) have been implicated to varying 
extents in the cytotoxic mechanisms of cisplatin 
(3), doxorubicin (4), bleomycin (5) and etoposide 
(6).  It is thought that ROS may be supplementing 
the primary mechanism of toxicity of each of these 
agents. 
The small-molecule anticancer agent 11β (Fig. 
1A) was designed to kill androgen receptor (AR) 
positive prostate cancer cells by targeting both 
DNA replication (via its aniline mustard moiety, 
which forms DNA adducts) and the expression of 
steroid-responsive genes (via its steroid ligand).  
The structure of 11β features the DNA-reactive p-
N,N-bis-(2-chloroethly)aminophenyl group linked 
to an estradien-3-one ligand (Fig. 1A), which has a 
high affinity for the AR (7).  It was originally 
proposed that the DNA adducts formed by 11β 
could bind the AR and potentially disrupt tumor 
cell biology by two non-mutually exclusive 
mechanisms:  (i) antagonism of AR-regulated gene 
expression, and (ii) obstruction of the DNA repair 
process.  Recent studies demonstrate that 11β 
induces apoptosis in AR+ prostate cancer cells, is 
stable in vivo, and effectively prevents the growth 
of AR+ LNCaP tumors as xenografts in mice 
(7;8).  While very effective against AR+ cells and 
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tumors, 11β has surprisingly potent activity 
against AR- cells and tumors, leading to 
reconsideration of the role of the AR in the 
process leading to cell death.  The present study is 
the result of the search for AR-independent 
mechanisms of 11β toxicity.   
Previous studies (7) revealed that 11β induces 
apoptosis at lower exposure levels and much more 
rapidly than DNA damaging aniline mustard drugs 
such as chlorambucil (Fig.  1), which contains the 
same alkylating group.  Within 6 h of treatment 
with >5 µM 11β, LNCaP cells undergo 
cytoplasmic contraction and detachment from the 
culture dish, while treatment with similar or even 
higher concentrations of chlorambucil has little 
effect on cell morphology and does not induce 
apoptosis (7).  In addition, 11β-dim, a DNA-
unreactive analog of 11β (Fig. 1), produces similar 
morphological changes but does not induce 
apoptosis in the same concentration range (7), 
further suggesting the possibility of additional 
mechanisms of cytotoxicity. 
The current study demonstrated that 11β 
potently induced apoptosis in AR-negative HeLa 
cells both in vitro and when grown as xenograft 
tumors in mice.  Furthermore, both 11β and its 
analog, 11β-dim (Fig. 1), generated a burst of 
intracellular ROS, whereas in the same dose 
ranges, chlorambucil or the steroid moiety of 11β 
alone (estradien-3-one) did not.  The functional 
role of ROS was evidenced by co-treatment with 
antioxidants, which reduced ROS formation and 
suppressed the cytotoxicity of both 11β and 11β-
dim. Additional experiments indicated that 
mitochondria were the main intracellular sink for 
11β and an important source of the ROS, which 
were produced due to the specific inhibition of 
complex I of the mitochondrial electron transport 
chain (ETC).  Together, these findings established 
ROS production and complex I inhibition as new, 
DNA adduct independent mechanisms of 11β that 
supplemented the compound’s ability to kill tumor 
cells by covalent DNA damage. The data also 
suggested that 11β could be active against a wide 
range of tumors, including those that do not 
express the AR and added support the growing 
body of evidence that oxidative stress may 
synergize with conventional DNA adducts to 
promote cancer cell death. 
 
 
EXPERIMENTAL PROCEDURES 
 
Reagents- The compounds 11β and 11β-dim 
were synthesized as previously reported (7). 14C-
11β was prepared as described in (8). Stock 
solutions of test compounds were prepared in 
DMSO and stored at -80°C.  All chemical reagents 
were purchased from Sigma-Aldrich (St.Louis, 
MO, USA), unless indicated otherwise. 17β-
Hydroxy-estra-4(5),9(10)dien-3-one (estradien-3-
one) was obtained from Brighton Co. LTD, Chang 
Sha, Hunan, China.  CM-H2DCFDA, CM-
DCFDA, MitoSOX and JC-1 molecular dyes were 
obtained from Molecular Probes (Invitrogen, 
Carlsbad, CA, USA).  All cell media, media 
supplements, DPBS and HBSS were from 
Invitrogen. CTB reagent was purchased from 
Promega (Madison, WI, USA). 
Cell lines and culture- HeLa cells were 
obtained from American Type Culture Collection 
(Rockville, MD, USA) and maintained in Minimal 
Essential Medium (MEM) supplemented with 1 
mM glutamax, 1% non-essential amino acids, 1 
mM pyruvate, and 10% fetal bovine serum 
(Hyclone, Logan, UT, USA), in a humidified 5% 
CO2/air atmosphere at 37°C. 
Determination of cytotoxicity and cell 
viability- Clonogenic survival assays were 
performed by seeding 1×103 HeLa cells per well in 
6-well plates, followed by growth for 24 h to allow 
cell attachment.  Test compounds dissolved in 
DMSO were added to growth media for 24 h, 
replaced with fresh medium and growth continued 
for 3-5 days until colonies were clearly visible.  
Colonies were fixed with water:methanol:acetic 
acid (4:5:1), stained 0.5% crystal violet and 
manually counted.  The surviving fraction was 
calculated as the ratio of the number of colonies in 
treated well to the number in untreated wells. Cell 
viability was estimated using the Cell-Titer Blue 
(CTB) assay as described in the manufacturer’s 
instructions.  Briefly, 2.5×103 cells/well were 
seeded in black/clear bottom 96-well plates 
(Corning Inc., Corning, NY, USA) and incubated 
for 24 h.  Media was then replaced with fresh 
drug-containing media for the indicated times.  
CTB reagent was then added for 2-4 h after which 
fluorescence (ex/em: 555/585 nm) was measured.  
Cell viability was calculated as the ratio between 
the average background corrected signal in the 
treated wells and the untreated control wells.  
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Immunoblot analysis- Whole cell extracts of 
HeLa cells were prepared by lysis in RIPA 
solution according to manufacturer’s instructions 
(Santa Cruz Biotechnology, Santa Cruz, CA, 
USA).  Equal amounts of protein were separated 
by SDS-PAGE and transferred to Immobilon-P 
membranes (Millipore, Bedford, MA, USA).  
Membranes were probed with primary antibodies 
anti-caspase-3 (#9665), anti-caspase-9 (#9502), 
anti-PARP (# 9542) and secondary antibody anti-
rabbit IgG-HRP (#7074); all antibodies were from 
Cell Signaling Technology (Danvers, MA, USA). 
Detection of antibody complexes was achieved by 
PicoWest chemoluminescence reagent (Pierce, 
Rockford, IL, USA). 
Determination of intracellular ROS using flow 
cytometry- Intracellular ROS levels were 
measured with fluorometric dyes.  1 × 105 HeLa 
cells were seeded in 6-well plates and grown for 
24 hours. After the cells were exposed to test 
compounds for the indicated times, the cells were 
washed with PBS and exposed to a molecular 
probe solution in HBSS at 37°C.  The molecular 
probes and their final concentrations were:  CM-
H2DCFDA (2.5 µM), CM-DCFDA (2.5 µM) and 
MitoSOX (2 µM).  After incubation for 15 min at 
37°C, the cells were washed, trypsinized, 
resuspended in HBSS and analyzed on the FL1 
channel (CM-H2DCFDA, CM-DCFDA) or the 
FL2 channel (MitoSOX) of a Becton Dickinson 
FACSCanto II flow cytometer.  The results were 
analyzed with FACSDiva 6.0 software (BD, 
Franklin Lakes, NJ, USA). 
Determination of mitochondrial membrane 
potential- Mitochondrial inner membrane potential 
(∆Ψm) was estimated using the mitochondrial-
specific dye JC-1 according to a published flow 
cytometry protocol (9). Briefly, after treatment, 
cells were incubated at 37°C with a solution of JC-
1 in medium without phenol red for 30 min, then 
trypsinized, resuspended in PBS and analyzed on a 
FACSCanto II flow cytometer.  The mitochondrial 
membrane potential was estimated by the ratio 
between the red (FL2) and green (FL1) 
fluorescence. The results were analyzed with 
FACSDiva 6.0 software (BD). 
Determination of H2O2, lipid peroxidation and 
NADPH- Cellular levels of H2O2 were measured 
using the Quantichrom Peroxide Assay (Bioassay 
Systems, Hayward, CA, USA) according to the 
manufacturer’s instructions.  Lipid peroxidation 
was monitored using the OxiSelect TBARS assay 
(Cell Biolabs, Inc., San Diego, CA, USA) as 
described in the manufacturer’s instructions.  
Cellular NADPH content was measured using the 
EnzyChrom NADP/NADPH assay (BioAssay 
Systems) according to the manufacturer’s 
instructions.  In all assays, the results were 
normalized for protein content, determined using 
the Bradford reagent (Bio-Rad, Hercules, CA, 
USA). 
Fluorescence microscopy- Cells were grown 
on poly-lysine coated coverslips, in 6-well plates.  
The seeding and treatment with test compounds 
was performed identically to the viability assay.  
After treatment, the cells were stained for 10 min 
at 37 °C with 1 µM MitoSOX and 5 µM Hoechst 
33342 in HBSS, washed 3 times in fresh HBSS 
and imaged with a Nikon Eclipse fluorescence 
microscope. 
Cell fractionation and mitochondria isolation- 
The protocol was adapted from reference (10) with 
modifications. All steps were performed at 4°C. 3 
× 107 HeLa cells were detached by scraping, 
washed in cold DPBS and resuspended in 3 mL 
isolation buffer (Buffer IB: 10 mM Tris-MOPS, 1 
mM EGTA-Tris, 200 mM sucrose, pH = 7.4). The 
cells were disrupted with a tight-fitting Dounce 
homogenizer, on ice (30 strokes). The homogenate 
was sedimented at 800 × g for 10 min to yield a 
nuclear pellet. The supernatant was further 
sedimented at 8000 × g for 10 min to yield the 
mitochondrial pellet. Finally, the post-
mitochondrial supernatant was centrifuged at 
100,000 × g (Beckmann Ultracentrifuge) for 1 h to 
separate the microsomal fraction (pellet) from the 
cytosol (supernatant). For oxygen consumption 
studies, rat liver mitochondria were isolated using 
a similar protocol (10). Mitochondria isolated 
from fresh rat liver were kept on ice and used the 
same day. Total mitochondrial protein was 
determined by hydrolyzing mitochondrial aliquots 
in NaOH, 0.5 M and then using the Bradford 
method. 
Cellular localization of 11β- To determine the 
cellular distribution of 11β, HeLa cells were 
treated with 14C-11β for 6 h, then subjected to 
fractionation. Aliquots of each fraction were 
suspended in scintillation fluid (EcoScint H) and 
radioactivity was measured using a Beckmann LS 
6500 scintillation counter. 
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Oxygen consumption– Oxygen consumption 
was measured with a PreSens Fibox 3 (Precision 
Sensing, Regensburg, Germany) oxygen mini-
sensor, according to manufacturer’s instructions. 
All measurements were done at room temperature. 
For cellular oxygen consumptions, HeLa cells 
were washed, trypsinized and resuspended in cell 
culture medium at 5 × 106 cells/mL. Mitochondrial 
oxygen consumption was measured as described 
(10) using the substrates: 5mM glutamate/2.5 mM 
malate (complex I) or 5 mM succinate (complex 
II) or 6 mM ascorbate/300 µM TMPD 
(cytochrome c/complex IV). Mitochondria were 
suspended in experimental buffer (Buffer EB: 12.5 
mM KCl, 10 mM Tris-MOPS, 0.1 mM EGTA-
Tris, 1 mM KH2PO4, pH 7.4), at a concentration of 
2 mg/mL of mitochondrial protein. To measure 
NADH driven oxygen consumption, mitochondria 
were permeabilized to NADH using three freeze-
thaw cycles. 
ROS measurement in isolated mitochondria– 
Rat liver mitochondria (0.5 mg/mL protein 
concentration) were incubated at 37 °C in EB, 
supplemented with 0.1% BSA, 5 mM glutamate, 
2.5 mM malate, 0.05 U/mL horseradish peroxidase 
(HRP) and 10 µM Amplex Red reagent, in the 
presence of DMSO (control) or test compound, 
with or without 2000 U/mL of bovine liver 
catalase (Roche, Indianapolis, IN, USA). After 20 
minutes in the dark, the fluorescence of the 
resorufin generated by Amplex Red was 
monitored for 20 minutes in a SpectraMax M3 
spectrophotometer (Molecular Devices, 
Sunnyvale, CA, USA). The amount of H2O2 
generated was calculated from a H2O2 standard 
curve obtained in similar conditions.  
Complex I activity assay– Complex I activity 
was measured by using the synthetic electron 
acceptor decylubiquinone (Sigma) and monitoring 
the rate of NADH disappearance (11). Rat liver 
mitochondria were permeabilized to NADH with 3 
freeze-thaw cycles, diluted to 0.25 mg/mL (total 
mitochondrial protein) in potassium phosphate 
buffer (25 mM, pH 7.4) and supplemented with 
0.35% BSA, 1 µM antimycin, 1 mM KCN and 70 
µM decylubiquinone. NADH (0.1 mM) and the 
test compound (or DMSO control) were added 
last. After a brief and thorough mixing, the drop in 
the absorbance difference A340-A380 was monitored 
in a quartz cuvette on a Beckmann Coulter DU730 
Spectrophotometer at room temperature. Complex 
I activity was then calculated using εNADH for A340-
A380 as 5.5 mM-1 cm-1 (11). 
Tumor xenograft studies and immuno-
histochemistry- HeLa cells (6 x 106) suspended in 
50% PBS/50% Matrigel (BD) were injected 
subcutaneously in the right flank of 6-week old 
NIH Swiss nu/nu female mice.  Mice developing 
subcutaneous tumors within 2 weeks were 
randomized to treatment and control groups.  
Administration of test compound dissolved in 
cremophore EL, saline, ethanol (43:30:27) was 
begun when established tumors reached 
approximately 7 mm diameter.  Tumor 
measurements obtained with vernier calipers and 
tumor volumes estimated using the formula 
(width2 × length × 3.14)/6.  Experiments were 
carried out under the guidelines of the MIT 
Animal Care Committee. 
Statistical analysis- All results are expressed 
as mean ± standard deviation. The significance of 
the difference between two populations was 
calculated using Student’s two-tailed t-test for 
unpaired data sets with unequal variances. P-
Values less than 0.05 were considered significant.  
The LC50 and EC50 values were calculated from 
the dose response curves by using 4 variable 
logistic curve fitting function in Prism 3.0 for 
Windows (GraphPad Software Inc., San Diego, 
CA, USA). 
 
RESULTS 
 
The toxicity of 11β towards HeLa cells. Our 
investigations sought to uncover mechanisms of 
toxicity that were unrelated to the affinity of 11β 
for the AR.  HeLa cells, which do not express the 
AR (12), were chosen to assess the respective 
contributions of the steroid and alkylating portions 
of the compound (Fig.  1).  Chlorambucil was used 
as a model of the reactive alkylating portion of 
11β since both molecules share the p-N,N-bis-(2-
chloroethyl)aminophenyl group that can form a 
reactive aziridine capable of covalent modification 
of DNA and other cellular molecules.  To 
investigate the non-covalent interactions of 11β, 
an analog, 11β-dim (Fig. 1A) was prepared. This 
compound was unreactive towards the model 
nucleophile 4-(4-nitro-benzyl)-pyridine (NBP) 
(Supplemental data, Fig.  S1), indicating that it 
lacked the ability to modify DNA covalently. It 
was thus expected that any observed 11β-dim 
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toxicity would arise only from non-covalent 
interactions with cellular targets. 
 Cell viability analysis, performed using the 
CellTiter Blue (CTB) assay (Fig.  1B), revealed a 
steep dose response to concentrations of 11β >5 
µM, and a similar steep response observed at 
higher concentrations (>12 µM) with 11β-dim.  By 
contrast, neither chlorambucil nor estradiene-3-
one at 20 µM decreased the CTB signal by more 
than 25% (Fig. 1B). Both 11β and 11β-dim 
exhibited a threshold effect above which cell 
viability rapidly decreased; such an effect was not 
observed with either chlorambucil or estradiene-3-
one. 
Given the striking decrease in viability that 
was observed after a 24 h treatment with 11β, it 
was of interest to determine the effect of shorter 
exposure times on cell viability.  HeLa cells were 
exposed to increasing concentrations of 11β for 3, 
6 or 24 h and cell viability was measured at 24 h.  
Comparable toxicities were achieved for 6 or 24 h 
exposures to 11β (6 h, EC50 = 5.3 ± 0.3 µM; 24 h, 
EC50 = 4.9 ± 0.3 µM), while a 3 h exposure period 
resulted in lower levels of toxicity (Fig. 1C). 
Together, these data suggested that a 6 h exposure 
was sufficient for achieving maximum toxicity of 
11β for most doses. Therefore, subsequent 
mechanistic experiments focused on cellular 
changes that occur during the initial 6 h. 
Activation of apoptotic pathways by 11β was 
previously observed in LNCaP cells (7).  To 
determine whether apoptosis was also the 
mechanism of cell death in HeLa cells, the 
proteolytic cleavage of caspase-9, caspase-3 and 
poly-ADP ribose polymerase (PARP) were 
investigated. Western analysis with corresponding 
antibodies revealed that a 6 h treatment with 7.5 
µM or 10 µM 11β induced cleavage of caspase-9, 
caspase-3 and PARP (Fig. 1D). 
11β accumulates in the mitochondria. To 
understand better the putative targets of 11β, an 
intracellular localization study was performed. 
HeLa cells were treated with 5 µM 14C-labeled 
11β for 6 h, isolated and subjected to subcellular 
fractionation (see Materials and Methods). By 
measuring the radioactivity associated with the 
medium and the cell pellet, it was found that a 
significant portion of the total compound (over 
30%) becomes associated with the cells in 6 h 
(Fig. 2A). Subcellular fractionation revealed that 
50 ± 2% of the radioactive compound is found in 
the mitochondrial fraction, while the rest is 
distributed among the nucleus, microsomes and 
cytosol (Fig. 2B). The radioactivity measurements 
also allowed the estimation of the local 
concentration of 11β (Fig. 2C), the compound 
being most concentrated in the mitochondria (9.9 
± 0.4 pmol/µg protein) and the microsomes (8.5 ± 
0.5 pmol/µg protein). By assuming the volume of 
a HeLa cell of 4.2 pL (measured average diameter 
= 20 µm), the molar concentration of 11β in the 
cell after 6 h was estimated to be ~300 µM, a 60 
fold increase from the 5 µM concentration in the 
medium. Moreover, using the published value for 
the mitochondrial volume of 1.6 µL/mg 
mitochondrial protein (13), the molar 
concentration of 11β in the mitochondria was 
estimated to be ~6 mM , which is more than 1000 
fold increase from the medium concentration of 
11β. These findings suggest that mitochondria 
might be one of the targets of the compound. 
11β increases intracellular ROS. The 
observation that the DNA-unreactive 11β-dim is 
nevertheless toxic (Fig. 1B) indicated that 11β 
may be employing several mechanisms of toxicity. 
Given the rapid activation of the apoptotic 
pathway (Fig. 1C) and the mitochondrial 
localization of 11β (Fig. 2B), we hypothesized that 
one such mechanism may involve direct 
mitochondrial toxicity. 
One of the hallmarks of mitochondrial 
dysregulation is the generation of ROS and 
oxidative stress (14;15). Generation of ROS in 
HeLa cells was monitored using the molecular 
probe CM-H2DCFDA, which can detect most 
ROS at a cellular level (16). Once inside a cell, 
this probe is de-acetylated by cellular esterases 
and, when oxidized, it becomes the fluorescent 
compound CM-DCF, which can be detected in the 
FL1 channel of a flow cytometer.  Fig. 3A is a 
fluorescence histogram showing that treatment of 
HeLa cells for 6 h with 3 or 5 µM 11β resulted in a 
notable increase in CM-DCF fluorescence 
intensity (right shift) compared to DMSO (vehicle) 
treated cells.  The possibility that increased 
fluorescence was due to increased uptake of the 
probe was ruled out by use of a related molecular 
probe, CM-DCFDA, which does not require 
oxidation to become fluorescent.  When using 
CM-DCFDA, no significant increase in CM-DCF 
fluorescence was detected in the treated cells 
compared to controls, indicating that cellular 
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uptake of the dye was unaffected by 11β.  These 
findings together established that 11β treatment 
triggered a significant production of ROS. 
To determine whether the production of ROS 
required the ability of 11β to modify cellular 
molecules covalently, ROS levels were compared 
between cells treated for 6 h with 11β (5 µM) , 
11β-dim (10 µM), chlorambucil (10 µM) or 
estradien-3-one (10 µM) (Fig. 3B); antimycin A, a 
known ROS inducer, was included as a 
comparative control.  The data revealed that both 
11β compounds were potent inducers of ROS, 
while chlorambucil and estradien-3-one were not. 
Several other doses of each compound were 
investigated, revealing a dose-response 
dependence for 11β and 11β-dim (Supplemental 
data, Fig. S2). Thus, neither the ability to form 
covalent adducts (characteristic of 11β and 
chlorambucil), nor the presence of the steroid 
group (11β, 11β-dim and estradien-3-one) 
correlates with the ability to induce ROS. The 
operative structural feature responsible for the 
ROS induction appears to be the entire molecular 
framework of 11β or 11β-dim.  
To investigate the kinetics of intracellular 
ROS generation, a time course of ROS levels was 
measured in HeLa cells treated with 5 µM 11β.  
Increased levels of ROS were detected as early as 
30 min after addition of 11β to culture media and 
then the levels continued to increase in the first 6 h 
of exposure (Fig. 3C), suggesting that 11β caused 
both rapid-onset and sustained ROS generation.  
Several markers of oxidative stress in 11β-treated 
cells were also increased, including levels of 
hydrogen peroxide (Fig. 3D) and the secondary 
oxidation product, malondialdehyde (Fig. 3E). 
Additionally, the cellular levels of NADPH, the 
principal cellular reducing co-factor, decreased 
rapidly during the same time interval (Fig. 3F). 
These findings are consistent with the rapid 
formation of ROS in HeLa cells exposed to 11β 
suggesting that ROS and generalized oxidative 
stress may contribute to 11β cytotoxicity. 
Antioxidants decrease ROS levels and reduce 
11β toxicity. To establish a link between ROS 
production and the toxicity of 11β, HeLa cells 
were treated with 11β in the presence of 
antioxidants. A significantly lower level of ROS 
(p<0.01) was observed when HeLa cells were 
exposed to 5 µM 11β for 6 h in the presence of 
antioxidants N-acetyl-L-cysteine NAC (10 mM) or 
vitamin E (100 µM) (Fig. 4A).  Additionally, both 
NAC and vitamin E reduced the toxic effect of 
11β on cell viability, measured with the CTB 
assay.  The EC50 for 11β increased significantly 
from 4.9 ± 0.3 µM to 6.9 ± 0.7 µM in the presence 
of NAC and to 7.5 ± 0.1 µM in the presence of 
vitamin E (Fig.  4B).  Antioxidants also attenuated 
the adverse effect of 11β-dim on cell viability; the 
EC50 increased from 13.7 ± 0.3 µM to > 20 µM in 
the presence of NAC or vitamin E (Fig.  4C).  
Mitochondrial superoxide generation and 
increased ∆Ψm in 11β-treated cells. Mitochondrial 
ROS production was monitored with MitoSOX 
Red, a cationic dye that localizes in the 
mitochondria and specifically reacts with 
superoxide (O2●−). The product of this reaction (a 
2-hydroxyethidium derivative) can then be 
detected by fluorescence microscopy or FACS 
(17). HeLa cells treated with 5 µM 11β for 6 h 
showed increased MitoSOX fluorescence (Fig. 
5A), signaling the exaggerated production of O2●− 
by mitochondria.  A dose-response relationship 
revealed that concentrations of 11β >5 µM 
resulted in a significant O2●− production (Fig.  5B). 
To analyze further the effects of 11β on 
mitochondria, changes in the mitochondrial inner 
membrane potential (∆Ψm) were measured with 
the ∆Ψm indicator JC-1.  At 6 h, even low 
concentrations of 11β (< 5 µM) produced a 
significant increase in ∆Ψm (Fig. 5C), indicating a 
hyperpolarization of the mitochondrial inner 
membrane. A higher-than-normal ∆Ψm suggests a 
stalled  mitochondrial ETC, which leads to a 
higher electron density in the upstream 
mitochondrial carriers and an increased likelihood 
of stray electron transfer to O2 to generate 
superoxide (18).  To investigate further this 
sequence of events, ∆Ψm was measured in cells 
treated with 5 µM 11β in the presence of the 
antioxidants NAC and vitamin E. Although co-
treatment with antioxidants leads to lower cellular 
ROS levels (Fig.  4A), it does not affect the 
increase in ∆Ψm triggered by 11β (Fig. 5C). This 
finding suggests that the changes in the 
mitochondrial membrane precede ROS generation, 
and further establishes mitochondria as one of the 
targets of 11β. 
Effect of 11β on mitochondrial respiration. 
The perturbation of ∆Ψm and the increased 
formation of mitochondrial superoxide suggested 
that 11β could act as an inhibitor of mitochondrial 
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respiration, by interfering with the ETC. To test 
this hypothesis, the cellular oxygen consumption 
was measured first in intact HeLa cells. The cells 
were exposed to 5 µM 11β or DMSO control for 3 
h, then the oxygen consumption was measured 
using a Fibox 3 oxygen sensor, in the presence of 
1 nM FCCP (a potent uncoupler of mitochondrial 
oxidative phosphorylation). By using the 
uncoupler, the oxygen consumption measured 
reflected only the flow of the electrons through the 
ETC, irrespective of the energetic state (ATP 
levels) of the cell. The results indicated that cells 
treated with 11β had a 26 ± 7% lower respiration 
rate than untreated cells (Fig. 6A).  
To confirm the suppressive effect on cellular 
respiration, oxygen consumption was measured in 
isolated rat liver mitochondria, in the presence of 
various respiratory substrates. When mitochondria, 
uncoupled with 1 nM FCCP, were incubated with 
complex I substrates glutamate and malate, both 
11β and 11β-dim significantly (p<0.01) reduced 
the rate of oxygen consumption (Fig. 6B). 
Specifically, 10 µM of either compound caused a 
70 ± 5% decrease in respiration rate. In the same 
conditions, the potent complex I inhibitor, 
rotenone (1 µM) caused a 92 ± 5% decrease in 
respiration rate. However, when mitochondria 
were incubated with succinate, a complex II 
substrate, in the presence of rotenone (to block 
complex I activity), neither 11β or 11β-dim had 
any significant effect on the respiration rate (Fig. 
7B). Additional experiments, utilizing ascorbate 
and N,N,N’,N’-tetramethyl-p-phenylenediamine 
(TMPD), which are commonly used substrates to 
feed electrons into the ETC at the level of 
cytochrome c, downstream of complex III (10), 
showed no inhibition of oxygen consumption by 
11β or 11β-dim (data not shown). Together, these 
observations suggest that the main target of the 
11β compounds in the ETC is complex I. 
11β is an inhibitor of the mitochondrial NADH 
dehydrogenase (complex I). To confirm the 
hypothesis that 11β inhibits mitochondrial 
complex I, oxygen consumption of isolated 
mitochondria was measured using NADH as a 
substrate. Because NADH cannot freely diffuse 
through mitochondrial membranes, mitochondria 
were first permeabilized with three freeze-thaw 
cycles, and then oxygen consumption rate was 
measured as above. Both 11β and 11β-dim 
inhibited NADH-driven mitochondrial respiration 
(Fig. 6C). In these conditions, the 11β compounds 
achieved inhibition levels comparable to those of 
rotenone. To validate this result further, the effect 
of 11β on complex I was assessed using a direct 
mitochondrial NADH dehydrogenase assay. This 
assay utilizes permeabilized mitochondria and 
measures the oxidation rate of NADH in the 
presence of decylubiquinone, a synthetic electron 
acceptor specific to complex I (see Materials and 
Methods). Doses of 5 and 10 µM 11β significantly 
inhibited the oxidation rate of NADH (Fig. 6D). 
Taken together, these data established complex I 
as the direct target of 11β in the mitochondria. 
Generation of ROS in isolated mitochondria.  
The relationship between complex I inhibition and 
ROS production was also examined in isolated 
mitochondria. Intact rat liver mitochondria, 
charged with complex I substrates glutamate and 
malate, were incubated with DMSO control, 11β, 
11β-dim or rotenone, in the presence or absence of 
2000 U/mL of catalase. After 20 min, the Amplex 
Red reagent was added to quantitate the rate of 
H2O2 generation. Both 11β compounds increased 
significantly (p <0.01) the rate of H2O2 production 
in isolated mitochondria (Fig. 6E). The increase in 
rate (22 ± 6% for 10 µM 11β) was comparable to 
that caused by rotenone (1 µM), a known ROS 
inducer and mitochondrial toxin. Additionally, in 
the presence of catalase, an enzyme that breaks 
down H2O2, no significant increase was observed 
(Fig. 6E), suggesting that H2O2, resulting 
presumably from the dismutation of superoxide, 
was the main ROS diffusing out of the 
mitochondria in the presence of 11β.  
Toxicity of mixtures of 11β-dim and 
chlorambucil. While both 11β and 11β-dim induce 
ROS and have similar inhibitory effects on the 
mitochondrial ETC, 11β is more toxic (Fig. 1B). 
In a clonogenic survival assay (Fig. 7), 11β (LC50 
= 1.7 ± 0.1 µM) had much greater toxicity toward 
HeLa cells than either 11β-dim (LC50 = 8.1 ± 0.1 
µM) or chlorambucil (LC50 > 10 µM). To test 
whether the combination of ROS and the covalent 
modification of cellular molecules was responsible 
for 11β’s increased cytotoxicity, a clonogenic 
survival assay was performed with HeLa cells 
treated with equimolar mixtures of chlorambucil 
and 11β-dim.  The equimolar mixture of the two 
compounds had a greater toxicity (LC50 = 6.3 ± 0.1 
µM) than either compound alone (Fig. 7). In fact, 
the LC50 value was nearly identical to the 
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theoretical value corresponding to the linear 
addition of toxicities of the two compounds. 
However, the toxicity of the equimolar mixture did 
not reach the potency of 11β itself (LC50 = 1.7 ± 
0.1 µM), suggesting that the two mechanisms of 
toxicity synergize only when the molecular feature 
responsible for ROS and the feature responsible 
for covalent DNA adduct formation are present in 
the same molecular structure. 
Effects of 11β treatment on HeLa mouse 
xenograft tumors. A previous report demonstrated 
that 11β is very effective in preventing the growth 
of LNCaP (AR+) prostate cancer cell xenografts in 
nude mice (7). The remarkable toxicity of 11β 
against HeLa cells (an AR- cell line) in cell culture 
predicted that the compound could be active 
against AR-independent tumors. Accordingly, 
mice bearing HeLa tumor xenografts were treated 
with three consecutive weekly 5-day cycles with a 
daily dose of 30 mg/kg (i.p.), while control 
animals received vehicle only.  This treatment 
regimen produced a strong inhibition of tumor 
growth in the mice that received 11β (Fig. 8). 
 
DISCUSSION 
 
11β was designed to act by producing covalent 
DNA adducts that form complexes with the AR.  
In accord with predictions, 11β rapidly induces 
apoptosis in the AR-positive LNCaP cells (7). It is 
shown here that HeLa cells, which do not express 
the AR, are also rapidly killed by 11β, suggesting 
additional, AR-independent mechanism(s) of 
action. This study demonstrates that 11β 
unexpectedly accumulates in the mitochondria and 
inhibits the mitochondrial ETC at complex I, 
leading to an overproduction of ROS and 
oxidative stress. The direct mitochondrial toxicity 
and the production of ROS are novel toxicological 
supplements to the original design features of 11β. 
11β was found to cause a rapid increase in the 
intracellular levels of ROS and biomarkers of 
oxidative stress (Fig. 3).  Evidence of the 
involvement of ROS in 11β toxicity was provided 
by the abilities of the antioxidants NAC and 
vitamin E to lower the amounts of intracellular 
ROS (Fig. 4A) and increase cell viability (Fig. 
4B). The overproduction of ROS in 11β-treated 
HeLa cells was not dependent on the ability of the 
compound to form DNA adducts, as evidenced by 
the observation of comparable levels of ROS in 
cells treated with 11β or the DNA-unreactive 
analog 11β-dim (Fig. 3B).  Furthermore, no 
significant ROS production was detected in cells 
treated with either estradien-3-one (the steroid 
moiety of 11β) or chlorambucil (the alkylating 
moiety), suggesting that the entire molecular 
scaffold of 11β or 11β-dim was responsible for 
inducing ROS production. It is noteworthy that the 
11β-dim compound was less toxic than 11β, 
indicating that the alkylating functionality also 
makes a significant contribution to toxicity.  
The mechanism by which 11β stimulates the 
increased production of ROS appears to be the 
inhibition of mitochondrial ETC due to the direct 
inhibition of the NADH dehydrogenase (complex 
I). A number of experimental observations support 
this view. Firstly, subcellular localization studies 
showed that 11β accumulates in the mitochondria 
of HeLa cells. This observation is consistent with 
the biophysical properties of the 11β molecule, 
which is both highly hydrophobic (logP value ~5), 
and positively charged (the secondary amine 
functionality in the linker is predominantly 
protonated at physiological pH). Many lipophilic 
cations, such as cationic aromatic dyes and 
triphenyl phosphonium conjugates are known to 
accumulate in mitochondria (19;20). Secondly, 
11β disrupted inner mitochondrial membrane 
potential (Fig. 5C) and cellular respiration 
(Fig. 6A), observations consistent with 
mitochondrial toxicity. Even a non specific 
accumulation of 11β within the mitochondrial 
membrane could disrupt the flow of electrons 
through ETC leading to increased ∆Ψm, which in 
turn could lead to increased ROS production 
(18;21). Thirdly, experiments with isolated 
mitochondria indicated that 11β inhibited 
mitochondrial respiration specifically at complex I 
(Fig. 6B, 6C). When mitochondria were incubated 
with substrates that feed electrons into the ETC 
downstream of complex I, no inhibition was 
observed (Fig. 6B). Further experiments 
confirmed the inhibitory effect of 11β on the 
NADH dehydrogenase (complex I) (Fig. 6C, 6D). 
Finally, complex I inhibition by 11β was shown to 
be sufficient to increase the rate of production of 
H2O2 in isolated mitochondria (Fig. 6E), providing 
a mechanistic explanation for the increased 
mitochondrial superoxide production (Fig. 5A) 
and general oxidative stress observed in cells 
treated with 11β (Fig. 3). These observations are in 
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good agreement with the currently accepted model 
of mitochondrial ROS production being due to 
ETC stalling and electron leakage from complexes 
I and III (21). These stray electrons incompletely 
reduce molecular oxygen to generate superoxide, 
an ROS confined to the mitochondria due to its 
charge. The activity of the mitochondrial 
superoxide dismutase then converts superoxide 
into oxygen and hydrogen peroxide, the latter 
being able to diffuse out of the mitochondria (21).   
Mitochondrial toxicity leading to oxidative 
stress is a known cytotoxic mechanism for other 
compounds with clinical relevance. For example, 
the cytotoxicity of the antileukemic drug 
adaphostin has been attributed to its ability to 
localize in the mitochondrial membranes where it 
inhibits complex III resulting in the generation of 
ROS (22). Similarly to 11β, adaphostin 
accumulates to milimolar concentrations in the 
mitochondria; blocks cellular and mitochondrial 
respiration; perturbs mitochondrial inner 
membrane potential; and exhibits a cytotoxicity 
that can be ameliorated by co-treatment with 
antioxidants (22). However, not all compounds 
that generate oxidative stress interact with 
mitochondria directly. Compounds such as 
cisplatin (3), staurosporine (23) and the 
proteasome inhibitor bortezumib (24) are known 
to increase ∆Ψm leading to increased ROS 
production, but in each case, the effect is 
apparently not due to a direct interaction with the 
mitochondria, but rather to a perturbation of the 
metabolic pathways involved in maintaining 
cellular redox homeostasis. In addition to its direct 
effect on the mitochondria, 11β also perturbs the 
cellular redox homeostasis as evidenced by the 
rapid decline in cellular NADPH levels (Fig. 3F). 
Whether this effect is due solely to the increased 
cellular ROS levels, or there is a different 
metabolic pathway affected by 11β, remains the 
object for further investigation. 
Agents that induce oxidative stress have 
already been used to sensitize resistant cancer cells 
to alkylating drugs and radiation (25-27). There is 
also evidence that cancer cells are more sensitive 
to ROS induction than differentiated cells (2). 
Indeed, the generation of ROS and the concurrent 
depletion of antioxidant capacity can result in 
activation of stress-responsive genes leading to 
apoptosis or necrosis (2;28). One of the challenges 
of this therapeutic approach is matching both the 
pharmacokinetic and pharmacodynamic properties 
of different treatment protocols to enhance tumor 
response (29).  The 11β compound represents a 
simplified approach by incorporating two 
mechanisms into a single molecule (Fig. 9) as 11β 
is both a DNA-alkylating compound (8) and a 
potent inducer of oxidative stress (current study).  
Furthermore, whereas alkylating agents such as 
chlorambucil have been found to induce only a 
transient oxidative stress response at high doses 
(30), 11β induces a sustained generation of ROS 
that may be more effective in sensitizing cells by 
antioxidant depletion. The sustained oxidative 
stress induced by 11β is likely due to its 
mitochondrial accumulation and specific ETC 
inhibition at complex I. Given the effectiveness of 
11β against cancer cells both in cell culture (Fig. 
1B) and in tumor xenografts (Fig. 8), 
understanding the detailed molecular mechanism 
of complex I inhibition remains an important 
stepping stone for pre-clinical development and 
warrants further investigation.     
Continued interest in 11β as a potential 
anticancer drug stems from its ability to inhibit the 
growth of prostate tumors in xenograft animal 
models (7), with minimal side-effects on the 
animal host.  We originally proposed that this 
anticancer activity is due to the ability of 11β-
DNA adducts to bind the AR and increase toxicity 
by interfering with the DNA repair process as well 
as by antagonizing the expression of AR-regulated 
genes. In this report we demonstrate cytotoxic 
activity against another tumor cell line (HeLa), 
which lacks the AR, and characterize an additional 
mechanism of toxicity that involves mitochondrial 
ETC complex I inhibition and ROS generation. 
The combined actions of 11β in targeting both the 
mitochondrion and the nucleus (Fig. 9) distinguish 
it from existing anticancer drugs that either solely 
generate ROS (i.e., quinones by redox cycling 
(31)) or primarily form DNA adducts (i.e., simple 
aniline mustards). However, the fact that 
equimolar mixtures of chlorambucil and 11β-dim 
did not recreate the potent toxicity of 11β (Fig. 7) 
suggests that the interplay between the two 
mechanisms of toxicity is more complex and 
requires further investigation. Nevertheless, the 
concurrent ability to akylate DNA and induce 
ROS by perturbing mitochondrial function appears 
to be a useful paradigm for the design of broad-
specificity antitumor compounds.
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FIGURE LEGENDS 
Fig. 1. Structures of compounds and their effects on HeLa cell viability and apoptosis. (A) The 
antitumor agent 11β is an aniline mustard linked to the steroid ligand estradiene-3-one (EDO). Similarly 
to chlorambucil (CMB), 11β contains the p-N,N-bis-(2-chloroethly)aminophenyl moiety capable of 
forming reactive aziridinium ions that produce covalent DNA adducts (DNA damage). The unreactive 
analog 11β-dim substitutes methoxy groups for chlorine atoms, which prevent formation of aziridinium 
ions and hence abolishes the ability to interact covalently with DNA. (B) Cell viability (estimated with 
the CTB assay) following 24 h treatment with 11β, 11β-dim, CMB or EDO.  (C) Cell viability (assayed at 
24 h) following treatments with the indicated concentrations of 11β for 3, 6, or 24 h. Cell viability was 
estimated using the CTB assay. The viable cell fraction was calculated relative to vehicle-treated controls.  
Data represent average ± standard deviation, n = 3. (D) Western blot analysis investigating the cleavage 
of PARP, caspase-9 and caspase-3 following treatment with 11β for 6 h. β-Actin is included as a loading 
control. Staurosporine (STS) is shown as a positive control. 
 
Fig. 2. Cellular uptake of 11β and intracellular localization. (A) 11β distribution between the medium 
and HeLa cells, after 6 h exposure to 5 µM 11β. (B) Relative intracellular localization of 11β in HeLa 
cells exposed for 6 h to 5 µM 11β. Subcellular fractionation was performed as described in Materials and 
Methods. (C) The concentration of 11β (in pmol/µg protein) in the subcellular fractions from part B. Data 
represent mean ± standard deviation, n = 3.  
 
Fig. 3.  Effects of 11β compounds on ROS levels and markers of oxidative stress in HeLa cells. (A) 
Representative histograms of flow cytometry experiments demonstrating increased fluorescence intensity 
of CM-DCF (the oxidized form of CM-H2DCFDA) following treatment with 3 µM or 5 µM 11β for 6 h. 
(B) Quantitative estimates of changes in mean fluorescence intensity of CM-DCF following 6 h 
treatments with 5 µM 11β , 10 µM 11β-dim, 10 µM estradien-3-one (EDO) or 10 µM chlorambucil 
(CMB) as measured by flow cytometry.  Antimycin A (AMA), used at 1 µM is shown as a positive 
control.  (C-F) Time course of the levels of ROS and markers of oxidative stress after exposure to 5 µM 
11β. (C) Time-dependent changes in mean fluorescence intensity of CM-H2DCFDA as measured by flow 
cytometry; (D) H2O2 concentration; (E) malonic dialdehyde (MDA) concentration; (F) total cellular 
NADPH concentration.  Assays performed as described in Materials and Methods.  Data represent mean 
± standard deviation, n = 3. * p<0.05, ** p<0.01. 
 
Fig. 4. The effect of antioxidants on the toxicity of 11β compounds in HeLa cells. (A) HeLa cells 
were treated with 5 µM 11β for 6 h in the presence of NAC (10 mM), vitamin E (100 µM) or vehicle 
(DMSO).  Cells were then loaded with CM-H2DCFDA and the mean fluorescence intensity determined 
by flow cytometry.  (B) Cell viability following 24 h treatment with 11β alone or in the presence of NAC 
(10 mM) or vitamin E (100 µM).  (C) Cell viability following 24 h treatment with 11β-dim alone or in the 
presence of NAC (10 mM), vitamin E (100 µM). Data represent average ± standard deviation, n = 3; * 
p<0.05, ** p<0.01. 
 
Fig. 5.  Effects of 11β on superoxide levels and ∆Ψm in HeLa cells.  (A) Cells were treated with 
DMSO (left panels) or 5 µM 11β for 6 h (right panels) then loaded with the mitochondrial O2●− indicator 
MitoSox Red and Hoechst 33342 and imaged by fluorescence microscopy.  Top panels display enhanced 
mitochondrial O2●− production in 11β-treated cells.  Middle panels show nuclear staining for reference.  
Bottom panels show merged images.  Magnification is 100×.  (B)  Quantitative estimates of dose-
dependent changes in mean fluorescence intensity of MitoSox Red following 6 h treatments with 11β as 
measured by flow cytometry.  (C)  11β-induced changes in ∆Ψm.  Cells were treated with the indicated 
concentrations of 11β for 6 h in the absence or presence of NAC (10 mM) or Vitamin E (100 µM).  The 
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cells were then loaded with JC-1 dye and the fluorescence measured by flow cytometry.  Data represent 
mean ± standard deviation, n = 3, * p <0.05, ** p<0.01. 
 
Fig. 6. Effects of 11β on cellular and mitochondrial respiration. (A) Cellular oxygen consumption was 
measured as described in Materials and Methods. HeLa cells were treated with 5 µM 11β or DMSO for 2 
h, then oxygen consumption was measured in the presence of FCCP (1 nM), a mitochondrial ETC 
uncoupler. (B) Oxygen consumption in isolated rat liver mitochondria uncoupled with FCCP (1 nM). To 
test the electron flow through ETC via complexes I-III-IV, a glutamate/malate mix was used as a 
substrate. Rotenone (ROT), 1 µM was used as a control. To test the electron flow via complexes II-III-IV, 
succinate and rotenone (1 µM final) were used. In each case, oxygen consumption was determined in the 
presence of DMSO control, 11β or 11β-dim at the indicated concentrations. (C) Oxygen consumption in 
isolated rat liver mitochondria, using NADH as a substrate. The mitochondria were permeabilized to 
NADH by 3 freeze-thaw cycles. Rotenone (1 µM) was used as a control.  (D) Complex I activity was 
measured in permeabilized mitochondria, by spectrophotometrically monitoring the disappearance of the 
NADH substrate. Decylubiquinone was used as the final electron acceptor. Rotenone (1 µM) was used as 
a positive control. Data represent average ± standard deviation, n = 3.  (E) Production of H2O2 in isolated 
rat liver mitochondria following exposure to the 11β compounds. Mitochondria, charged with 
glutamate/malate, were exposed for 20 min at 37 °C to the indicated amounts of 11β, 11β-dim, or 
rotenone control (1 µM), in the presence or absence of 2000 U/mL of bovine liver catalase. The rate of 
H2O2 produced was then determined using the Amplex Red method. Data respresent average ± standard 
deviation, n = 4, * p<0.05, ** p<0.01. 
 
Fig. 7. Clonogenic survival of HeLa cells treated with 11β, 11β-dim, chlorambucil or 11β-
dim/chlorambucil equimolar mixture. Surviving fraction was determined by staining and counting 
colonies after 7 days. Data represent mean ± standard deviation, n = 3. 
 
Fig. 8. Effect of 11β treatment on HeLa tumor xenografts.  Mice bearing established HeLa tumors 
were dosed by daily injection with 30 mg/kg 11β or vehicle only. Points, mean tumor volume; bars, SD; 
horizontal bars, periods of dosing. 
 
Fig. 9. The proposed mechanisms of toxicity.  The substantial antitumor activity of 11β is proposed to 
be due to its ability to utilize two distinct mechanisms of toxicity: (i) DNA adduct formation and (ii) 
mitochondrial ROS production. Similarly to other nitrogen mustards, such as chlorambucil (top) 11β 
forms covalent DNA adducts (DNA damage).  However, 11β is also a potent mitochondrial respiration 
inhibitor and oxidative stress inducer. The second mechanism of toxicity is recapitulated by 11β-dim 
(bottom), the dimethoxy derivative of 11β that cannot form DNA adducts, suggesting that the two 
mechanisms are distinct. The concurrent ability of 11β to damage DNA and induce mitochondrial ROS 
appears to be a useful paradigm for the design of broad-specificity antitumor agents.
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